Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in osteoblasts

被引:78
|
作者
Takami, M
Takahashi, N
Udagawa, N
Miyaura, C
Suda, K
Woo, JT
Martin, TJ
Nagai, K
Suda, T
机构
[1] Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan
[2] Tokyo Inst Technol, Dept Bioengn, Yokohama, Kanagawa 2268501, Japan
[3] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Biochem, Tokyo 1920392, Japan
[4] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
关键词
D O I
10.1210/en.141.12.4711
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) produced by osteoblasts/stromal cells are involved as positive and negative regulators in osteoclast formation. Three independent signals have been proposed to induce RANKL expression in osteoblasts/stromal cells: vitamin D receptor-, cAMP-, and gp130-mediated signals. We previously reported that intracellular calcium-elevating compounds such as ionomycin, cyclopiazonic acid, and thapsigargin induced osteoclast formation in cocultures of mouse bone marrow cells and primary osteoblasts. Increases in calcium concentration in culture medium also induced osteoclast formation in cocultures. Treatment of primary osteoblasts with these compounds or with high calcium medium stimulated the expression of both RANKL and OPG messenger RNAs (mRNAs). 1,2-Bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)-tetra(acetoxymethyl)ester, an intracellular calcium chelator, suppressed both ionamycin-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C, also stimulated osteoclast formation in these cocultures and the expression of RANKL and OPG mRNAs in primary osteoblasts. Protein kinase C inhibitors such as calphostin and staurosporin suppressed ionomycin- and PMA-induced osteoclast formation in cocultures and expression of RANKL and OPG mRNAs in primary osteoblasts. Ionomycin stimulated RANKL mRNA expression in ST2 and MC3T3-G2/PA6 cells, but not in MC3T3-E1 or NIH-3T3 cells. These effects were closely correlated with osteoclast formation in response to ionomycin in cocultures with these stromal cell lines. OPG strongly inhibited osteoclast formation induced by calcium-elevating compounds and PMA in cocultures, suggesting that RANKL expression in osteoblasts is a rate-limiting step for osteoclast induction. Forskolin, an activator of cAMP signals, also stimulated osteoclast formation in cocultures. Forskolin enhanced RANKL mRNA expression but suppressed OPG mRNA expression in primary osteoblasts. These results suggest that the calcium/protein kinase C signal in osteoblasts/stromal cells is the fourth signal for inducing RANKL mRNA expression, which, in turn, stimulates osteoclast formation.
引用
收藏
页码:4711 / 4719
页数:9
相关论文
共 50 条
  • [41] Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer
    Mikosch, P.
    Igerc, I.
    Kudlacek, S.
    Woloszczuk, W.
    Gallowitsch, H. J.
    Kresnik, E.
    Stettner, H.
    Grimm, G.
    Lind, P.
    Pietschmann, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (08) : 566 - 573
  • [42] Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)
    Terpos, Evangelos
    Christoulas, Dimitrios
    Dimopoulos, Meletios-Athanassios
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (11) : 1265 - 1269
  • [43] Changes in Serum Receptor Activator for Nuclear Factor κB Ligand and Osteoprotegerin After Glucocorticoid Therapy Reflect Regulation of Their Expression by Glucocorticoid in Osteoblasts in Vitro
    Kaneko, Kaichi
    Kusunoki, Natsuko
    Tanaka, Nahoko
    Yamamoto, Tatsuhiro
    Kusunoki, Yoshie
    Takagi, Kenji
    Endo, Hirahito
    Kawai, Shinichi
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S440 - S440
  • [44] Expression of receptor activator of nuclear factor-κB ligand by B cells in response to oral bacteria
    Han, X.
    Lin, X.
    Seliger, A. R.
    Eastcott, J.
    Kawai, T.
    Taubman, M. A.
    ORAL MICROBIOLOGY AND IMMUNOLOGY, 2009, 24 (03): : 190 - 196
  • [45] Emerging Roles for Osteoprotegerin and Receptor Activator of Nuclear Factor-κB in the Vascular System
    Cozzolino, Mario
    BLOOD PURIFICATION, 2009, 28 (04) : 346 - 347
  • [46] Receptor activator of nuclear factor-κB ligand and osteoprotegerin -: Potential implications for the pathogenesis and treatment of malignant bone diseases
    Hofbauer, LC
    Neubauer, A
    Heufelder, AE
    CANCER, 2001, 92 (03) : 460 - 470
  • [47] Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-κB (NF-κB) ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvarial bones
    Swanson, Charlotte
    Lorentzon, Mattias
    Conaway, H. Herschel
    Lerner, Ulf H.
    ENDOCRINOLOGY, 2006, 147 (07) : 3613 - 3622
  • [48] Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-κB ligand and osteoprotegerin in plasma and serum
    Chan, BYY
    Buckley, KA
    Durham, BH
    Gallagher, JA
    Fraser, WD
    CLINICAL CHEMISTRY, 2003, 49 (12) : 2083 - 2085
  • [49] Differential expression of receptor activator of nuclear factor kappa B ligand and osteoprotegerin in calcific aortic stenosis
    Kaden, JJ
    Bickelhaupt, S
    Kilic, R
    Sarikoc, A
    Lang, S
    Haase, KK
    Dempfle, CE
    Borggrefe, M
    EUROPEAN HEART JOURNAL, 2003, 24 : 149 - 149
  • [50] Expression of Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor Kappa B Ligand in the Aortic Valve Calcification
    Voronkina, I. V.
    Irtyuga, O. B.
    Smagina, L., V
    Adamova, P. E.
    Zhiduleva, E., V
    Malashicheva, A. B.
    Sibagatullina, Y. S.
    Kruk, L. P.
    Gordeev, M. L.
    Moiseeva, O. M.
    BIOCHEMISTRY MOSCOW-SUPPLEMENT SERIES B-BIOMEDICAL CHEMISTRY, 2019, 13 (02) : 173 - 178